Trials / Terminated
TerminatedNCT04995575
Dissecting the Pathways of Therapy Resistance in Early Breast Cancer
Dissecting the Pathways of Therapy Resistance in Early Breast Cancer: A Sub-study of the EORTC 10041/BIG 3-04 MINDACT Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Within the 1st step MINDACT patients who have already relapsed will be asked to participate. For these patients a biopsy of the metastasis should have been taken. A molecular analysis of the stored primary tumor sample and of the metastatic sample, using new technologies, will be performed, and the characteristics of both samples will be compared. Within the 2nd step a prospective collection of the metastasis samples will be implemented and analysis of biological material from relapsing MINDACT patients is foreseen. This process will provide insights on the biology of breast cancer and allow us to better understand mechanisms of resistance to therapies, contributing to overcoming this important problem.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | collection of the biopsy, blood samples | for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals. For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples |
Timeline
- Start date
- 2020-07-08
- Primary completion
- 2022-05-09
- Completion
- 2023-10-23
- First posted
- 2021-08-09
- Last updated
- 2024-02-22
Locations
5 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT04995575. Inclusion in this directory is not an endorsement.